US 12,311,026 B2
Therapeutic uses for sodium thiosulfate formulations
Alexander Smith, Apex, NC (US); and Rostislav Christov Raykov, Summit, NJ (US)
Assigned to Fennec Pharmaceuticals, Inc., Research Triangle Park, NC (US)
Filed by Fennec Pharmaceuticals, Inc., Research Triangle Park, NC (US)
Filed on Mar. 15, 2024, as Appl. No. 18/606,860.
Application 18/606,860 is a continuation of application No. 17/992,715, filed on Nov. 22, 2022, granted, now 11,964,018.
Application 17/992,715 is a continuation of application No. 17/849,477, filed on Jun. 24, 2022, granted, now 11,510,984, issued on Nov. 29, 2022.
Application 17/849,477 is a continuation of application No. 17/584,257, filed on Jan. 25, 2022, abandoned.
Application 17/584,257 is a continuation of application No. 17/005,997, filed on Aug. 28, 2020, granted, now 11,291,728, issued on Apr. 5, 2022.
Application 17/005,997 is a continuation of application No. 16/458,261, filed on Jul. 1, 2019, granted, now 10,792,363, issued on Oct. 6, 2020.
Claims priority of provisional application 62/693,503, filed on Jul. 3, 2018.
Claims priority of provisional application 62/693,502, filed on Jul. 3, 2018.
Prior Publication US 2024/0216511 A1, Jul. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 33/04 (2006.01); A61K 33/243 (2019.01); A61K 47/02 (2006.01); A61K 47/18 (2017.01); A61K 47/20 (2006.01)
CPC A61K 47/20 (2013.01) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 33/04 (2013.01); A61K 33/243 (2019.01); A61K 47/02 (2013.01); A61K 47/18 (2013.01); A61K 47/183 (2013.01)] 26 Claims
 
1. A method of reducing ototoxicity in a pediatric patient receiving a platinum based chemotherapeutic for the treatment of cancer sensitive to the platinum based chemotherapeutic comprising administering an effective amount of a pharmaceutical composition comprising sodium thiosulfate at a concentration of about 0.5 M and a stabilizer or mixture of stabilizers selected from alanine, arginine, aspartic acid, histidine, lysine, proline, glucose, sucrose, trehalose, glycerol, glycine, mannitol, sorbitol, sodium sulphate, ethylenediaminetetraacetic acid (EDTA), cyclodextrin, dextran, polyethylene glycol, polyvinylpyrrolidone, and tromethamine, wherein the pharmaceutical composition is adjusted if necessary to achieve a pH between 6.5 and 8.9, and wherein the pharmaceutical composition comprises no borate ions.